Astra Zeneca India (Astra Zeneca Pharma India Limited), led biopharmaceutical company has announced the full results from the clinical trials of it’s latest diabetes drug, Dapagliflozin.
According to a statement from the company Dapagliflozin shows significant benefits in reducing chronic kidney disease (CKD) progression in patients with and without type-2 diabetes.
This CKD benefit is over and above the superior anti-diabetic and heart failure benefits. Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that Dapagliflozin along with standard of care reduced the worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo in patients with chronic kidney disease (CKD).
The results were consistent in patients both with and without type-2 diabetes (T2D). Dr. Anil Kukreja, Vice President – Medical Affairs & Regulatory, Astra Zeneca India said, “ The DAPA-CKD trial which included 201 Indian patients with CKD into a global clinical study enrolling 4,304 patients, was able to show a benefit in patients with CKD.
Now this goes on show that Dapagliflozin which is effective in Type 2 Diabetes, select Heart Failure patients has demonstrated significant efficacy now even in Chronic Kidney Disease.”